GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Applied DNA Sciences Inc (FRA:UDJ) » Definitions » Return-on-Tangible-Equity

Applied DNA Sciences (FRA:UDJ) Return-on-Tangible-Equity : 0.00% (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Applied DNA Sciences Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Applied DNA Sciences's annualized net income for the quarter that ended in Mar. 2024 was €-16.45 Mil. Applied DNA Sciences's average shareholder tangible equity for the quarter that ended in Mar. 2024 was €-0.56 Mil. Therefore, Applied DNA Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was N/A%.

The historical rank and industry rank for Applied DNA Sciences's Return-on-Tangible-Equity or its related term are showing as below:

FRA:UDJ' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1089.37   Med: -182.55   Max: -68.83
Current: -335.24

During the past 13 years, Applied DNA Sciences's highest Return-on-Tangible-Equity was -68.83%. The lowest was -1,089.37%. And the median was -182.55%.

FRA:UDJ's Return-on-Tangible-Equity is ranked worse than
94.97% of 199 companies
in the Medical Diagnostics & Research industry
Industry Median: -5.75 vs FRA:UDJ: -335.24

Applied DNA Sciences Return-on-Tangible-Equity Historical Data

The historical data trend for Applied DNA Sciences's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied DNA Sciences Return-on-Tangible-Equity Chart

Applied DNA Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -918.22 -179.29 -74.27 -123.03

Applied DNA Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.40 -142.70 -305.97 -230.49 -

Competitive Comparison of Applied DNA Sciences's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, Applied DNA Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied DNA Sciences's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Applied DNA Sciences's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Applied DNA Sciences's Return-on-Tangible-Equity falls into.



Applied DNA Sciences Return-on-Tangible-Equity Calculation

Applied DNA Sciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Sep. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=-9.32/( (13.041+2.11 )/ 2 )
=-9.32/7.5755
=-123.03 %

Applied DNA Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-16.448/( (1.406+-2.527)/ 2 )
=-16.448/-0.5605
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Applied DNA Sciences  (FRA:UDJ) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Applied DNA Sciences Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Applied DNA Sciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied DNA Sciences (FRA:UDJ) Business Description

Traded in Other Exchanges
Address
50 Health Sciences Drive, Stony Brook, New York, NY, USA, 11790
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) nd ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.

Applied DNA Sciences (FRA:UDJ) Headlines

No Headlines